Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss

Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.

Previous post American Airlines swings to a loss, but tops estimates for Q2 forecast
Next post Harley-Davidson stock moves higher on stronger-than-expected profit